|
|
Overview
Highlights
News
Pipeline
Chart
Contacts
|
|
|
|
|
|
|
|
|
| | "Sales
of its HIV drug Fuzeon increased 16 percent in the first quarter, marketed
by Roche"
|
| |
|
| |
|
|
|
| Approximate
Financial Snapshot as of 5/10/07 |
|
| Shares
Outstanding |
15.3M |
| 52
Wk Hi/Lo |
13.85/
6.45
|
| Market
Cap |
$111.9M |
| Recent
Price |
$7.32 |
|
|
|
|
|
|
5/3/07
TRIMERIS
(TRMS)
Website:
www.trimeris.com
FUZEON, is the first
in a new class of anti-HIV drugs called fusion inhibitors.
Overview
Trimeris (TRMS) is
a biopharmaceutical company engaged in the discovery, development and
commercialization of novel therapeutic agents for the treatment of viral
disease. The core technology platform of fusion inhibition is based on
blocking viral entry into host cells. FUZEON, approved in the U.S., Canada
and European Union, is the first in a new class of anti-HIV drugs called
fusion inhibitors. Trimeris is developing FUZEON and future generations of
peptide fusion inhibitors in collaboration with F. Hoffmann-La Roche Ltd.
This is an abbreviated profile
and we encourage readers interested in learning more about Trimeris to visit
the company website at www.trimeris.com.
TRMS
Investor Highlights
- Announced sales of its HIV
drug Fuzeon increased 16 percent in the first quarter, driven by growth
outside the U.S. First-quarter net sales of the drug grew to $64.3
million, from $55.4 million a year ago.
- All sales of FUZEON are
recorded by F. Hoffmann-La Roche Ltd, ("Roche"), Trimeris'
collaborative partner.
- Has a collaboration agreement with Roche to develop and
market Fuzeon and T-1249, a replacement compound.
- Announced Roche will
return the rights to joint patents and other intellectual property
related to next-generation HIV fusion inhibitor peptides to Trimeris
that fall under the companies' 2000 research agreement.
Recent
News and Press Releases
Trimeris
Reports Financial Results for the First Quarter 2007
Trimeris
HIV Drug Sales Grow 16 Percent
Trimeris
Reports First Quarter 2007 FUZEON(R) Sales Results
For the latest Quote
and News on TRMS Click
Here.
Fuzeon
Approved in 2003, FUZEON® (enfuvirtide) is the first in a
class of anti-HIV drugs called fusion inhibitors. Its “mechanism of
action” (or the way it works) is completely different from existing
anti-HIV drugs. Instead of working on the inside of T cells (CD4) to stop
virus replication, FUZEON works on the outside where it can block entry
(“fusion”) to the cell. This unique function gives fusion inhibitors the
potential to treat resistant strains of HIV. Additionally, fusion inhibitors
are considered less likely to cause unwanted side effects and interfere with
other drugs. anti-viral
regimen.
The latest HIV treatment guidelines, issued by the US Department of Health
and Human Services, currently support the use of FUZEON in combination with
other anti-viral drugs to help treatment-experienced patients achieve
undetectable viral loads — the ultimate goal of anti-HIV therapy.
Pipeline
The introduction of an entry inhibitor (also known as fusion inhibitor)
revolutionized the treatment of HIV. With this breakthrough, patients could
fight the virus in a completely different way — from the outside of cells
instead of just from the inside. Trimeris' research continues to focus on
designing, developing, and commercializing new products that are more
effective, potent, and convenient for people affected by viral diseases.
Clinical Trials for T-1249
T-1249 is a second-generation fusion inhibitor for HIV. This compound
binds to a slightly different region of the HIV virus than FUZEON®
(enfuvirtide). As a result, T-1249 exhibits activity against FUZEON-resistant
viruses. In January 2004, the clinical development of T-1249 was put on hold
due to challenges in achieving the desired technical profile of the current
formulation. The compound's safety, efficacy, and tolerability were in no
way related to the decision. TRMS is currently advancing exciting fusion
inhibitor drug candidates toward IND and human studies in 2007.
Next-Generation Fusion Inhibitor
Trimeris and Roche entered into a Research Agreement in 2000 to discover and
develop Next Generation Fusion Inhibitor ("NGFI") peptide drug
candidates. The desired profile for a NGFI peptide is to maintain the highly
favorable efficacy and safety profile of FUZEON® (enfuvirtide),
while significantly improving patient convenience by reducing the number of
injections required for patient administration (i.e., targeting once per
week vs. FUZEON twice-daily dosing). Once-weekly dosing is unprecedented for
currently approved HIV drugs, which are now dosed either once- or
twice-daily.
In addition to having the characteristics indicated above, Trimeris has also
focused on creating NGFI compounds that demonstrate a high level of activity
against viruses that have developed resistance to FUZEON and, at the same
time, to provide a formidable barrier to the virus to impede development of
resistance. As such, these drug candidates possess the unique potential to
suppress virus replication in a more sustained, effective, and patient
friendly manner.
NGFI drug candidates in comparison to FUZEON
Trimeris and Roche have designed and evaluated numerous NGFI drug candidates
which could potentially meet the desired product profile described above.
Representative compounds from the NGFI program display the following
characteristics:
- Up to 7-fold improvement in potency against wild-type HIV clinical
isolates compared to FUZEON
- Up to 100-fold improvement in potency vs. FUZEON-resistant HIV
clinical isolates
- Much higher genetic barrier to development of viral resistance, as
measured in terms of the number of mutations in gp41 required for
resistance development
- Up to a 4-fold improvement in active drug clearance rate from
circulation in primates compared to FUZEON
In September, 2006 Trimeris and Roche agreed to amend their Research
Agreement to extend the Research Term by an additional two years from
January 1, 2007 through December 31, 2008. Research, development, and
commercialization costs for the NGFI program will continue to be split
equally by Trimeris and Roche, as will any profits from the worldwide sale
of products covered under the amended Research Agreement. Trimeris and Roche
have selected TRI-1144 as the lead NGFI preclinical compound due to its
favorable product profile, including potent antiviral activity against a
broad range of HIV clinical isolates and its attractive pharmacokinetic
properties in animals. The collaboration is currently focusing its efforts
on conducting additional in vitro and in vivo studies with
TRI-1144, including the development of extended release formulations for
this compound in order to meet the desired frequency of administration.
One
Month Chart
Contacts
Trimeris, Inc.
3500 Paramount Parkway
Morrisville, NC 27560
Phone: 919-419-6050
Fax: 919-419-1816
SEC Filings
TRMS filings with the SEC can be found here.
All Fillings are current and the Company is fully reporting.
Disclaimer
SmallCapReview.com
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases.
For continuing coverage of TRMS, please sign up for our free newsletter.
Information contained in this report was extracted from current documents
filed with the SEC, the company web site and other publicly available
sources deemed reliable. For more information see our disclaimer section, a
link of which can be found on our web site. This document contains
forward-looking statements, particularly as related to the business plans of
the Company, within the meaning of Section 27A of the Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. The information
provided in this report is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where such distribution or
use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a
Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out
to be. All materials presented on our web site and individual reports
released to the public through this web site, e-mail or any other means of
transmission are not to be regarded as investment advice and are only
for informative purposes. Before making a purchase or sale of any securities featured
on our web site or mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities representative.
This is not to be construed as a solicitation or recommendation to buy or
sell securities. As with any stock, companies we select to profile involve a
degree of investment risk and volatility. Particularly Small-Caps and OTC-BB
stocks. All investors are cautioned that they may lose all or a portion of
their investment if they decide to make a purchase in any of our profiled
companies. Past performance of our profiled stocks is not indicative of
future results. The accuracy or completeness of the information on our web
site or within our reports is only as reliable as the sources they were
obtained from. The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are subject to change
without notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold
positions in securities mentioned herein, and may make purchases or sales in
such securities featured on our web site or within our reports. In order to
be in full compliance with the Securities Act of 1933, Section 17(b),
SmallCapReview.com will disclose in it's disclaimer, what, if any
compensation was received for our efforts in researching, presenting
and disseminating this information to our subscriber database and featuring
the report on the SmallCapReview.com web site. SmallCapReview.com
has not been compensated for its efforts in presenting the Trimeris profile on its website and distributing it to its
database of subscribers. SmallCapReview.com
may decide to purchase or sell shares on a voluntary basis in the open
market before, during or after the profiling period of this report.
Information presented on our web site and within our reports contain
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be "forward
looking statements." Forward looking statements are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use
of words such as “expects’”, “will,” “anticipates,”
“estimates, “believes,” or that by statements indicating certain
actions “may,” “could,” or “might” occur.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE
INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP
SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its
web site.
|